ProCE Banner Activity

Current Biomarker Testing and Targeted Therapy Approaches for Pancreatic Cancer

Clinical Thought
In this commentary, review expert best practices in molecular testing and targeted therapy for patients with advanced pancreatic cancer.

Released: March 17, 2021

Expiration: March 16, 2022

No longer available for credit.

Share

Faculty

Rachna Shroff

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Ipsen Biopharmaceuticals Inc

Faculty Disclosure

Primary Author

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna Shroff, MD, has disclosed that she has received consulting fees from Agios/Clovis, Debiopharm, Exelixis, Incyte, Merck, QED Therapeutics, and Seattle Genetics and funds for research support from Exelixis, Merck, and Pieris/Taiho/Rafael.